methods to determine the effectiveness of a selective treatment of epidermal growth factor receptor in a patient, to treat a patient and to select a compound that inhibits the catalytically kinase activity of a variant epidermal growth factor receptor, probe, kit, compound that inhibits the catalytically kinase activity of a variant epidermal growth factor receptor, pharmaceutical composition, nucleic acid and isolated protein

摘要

METHODS FOR DETERMINING THE POSSIBILITY OF EFFECTIVENESS OF A SELECTIVE EPIDERMIC GROWTH FACTOR RECEPTOR TREATMENT IN A PATIENT, TO TREAT A PATIENT AND TO SELECT A COMPOUND THAT INHIBITS THE CATALYTIC ACTIVITY OF A RECEIVER SON RECEPTOR CINASE, KIT, COMPOUND THAT INHIBITS CATALYTIC ACTIVITY OF KINASE OF A VARIANT EPIDERMIC GROWTH FACTOR RECEIVER, PHARMACEUTICAL COMPOSITION, NUCLEIC ACID AND PROTEIN ISOLATED. The present invention relates to a method for determining cancer responsiveness to an epidermal growth factor receptor (EGFR) treatment. In a preferred embodiment, the presence of at least one variance in the kinase domain of the erbB | confers sensitivity to the gefitinib tyrosine kinase inhibitor. Thus, a diagnostic assay for these changes will allow the administration of gefitinib, erlotinib and other tyrosine synase inhibitors to those patients most likely responsive to the drug.